Medicare Drug Price Control Group Formed At CMS: How Will Stakeholders Interact?
Executive Summary
As the Centers for Medicare and Medicaid Services begins the process of building new price negotiation and inflation rebate programs within Medicare, stakeholders are watching to see how transparent the process will be and how much outside input the agency will seek.
You may also be interested in...
Medicare Price Inflation Rebate List Revisions A Sign Of IRA Implementation Overload?
The Centers for Medicare and Medicaid Services has a lot on its plate and is under intense stakeholder scrutiny as it implements the price control provisions of the Inflation Reduction Act.
CMS Building Rx Price Negotiating Staff Internally; Contracting With Outside Groups ‘Not On Radar’
CMS head Brooks-LaSure says agency is making progress in staffing the drug pricing control programs established by the Inflation Reduction Act. Medicare Center deputy director Cheri Rice will be its acting director under just-unveiled management structure.
CMS-Manufacturer Discussion Of Medicare Price Negotiation Program Scheduled For 13 December
Agency reaches out to manufacturers as it develops its approach to implementing the controversial new program.